Respiratory Disease Vaccines

Global Respiratory Disease Vaccines Market to Reach US$95.4 Billion by 2030

The global market for Respiratory Disease Vaccines estimated at US$91.7 Billion in the year 2024, is expected to reach US$95.4 Billion by 2030, growing at a CAGR of 0.7% over the analysis period 2024-2030. Viral Vaccine, one of the segments analyzed in the report, is expected to record a 0.6% CAGR and reach US$60.0 Billion by the end of the analysis period. Growth in the Bacterial Vaccine segment is estimated at 0.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.0 Billion While China is Forecast to Grow at 1.4% CAGR

The Respiratory Disease Vaccines market in the U.S. is estimated at US$25.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$16.8 Billion by the year 2030 trailing a CAGR of 1.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.2% and 0.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.3% CAGR.

Global Respiratory Disease Vaccine Market – Key Trends & Drivers Summarized

Why Is the Demand for Respiratory Disease Vaccines Growing Rapidly?

The demand for respiratory disease vaccines has surged due to the increasing prevalence of respiratory infections such as influenza, pneumonia, tuberculosis, and COVID-19. With respiratory diseases being a leading cause of morbidity and mortality worldwide, vaccination programs have become a primary strategy for disease prevention and public health management. Governments and healthcare organizations are implementing large-scale immunization campaigns to protect vulnerable populations, including children, the elderly, and individuals with chronic conditions. Additionally, the rise of pandemic threats has reinforced the importance of vaccine research and development, leading to accelerated regulatory approvals and increased funding for respiratory vaccine innovations. As global health authorities emphasize preventive healthcare, the market for respiratory disease vaccines continues to expand.

How Are Technological Advancements Enhancing Respiratory Vaccine Development?

Breakthroughs in vaccine development, including mRNA technology, recombinant protein vaccines, and nanoparticle-based delivery systems, have revolutionized the production and efficacy of respiratory disease vaccines. The success of mRNA vaccines during the COVID-19 pandemic has paved the way for further innovations in rapid vaccine development and scalability. Additionally, advancements in adjuvant formulations have improved vaccine immunogenicity, ensuring stronger and longer-lasting immune responses. AI-driven predictive modeling and genomic sequencing have also enhanced vaccine strain selection for influenza and other respiratory pathogens, optimizing annual vaccination programs. These technological advancements are enabling faster production cycles, better vaccine stability, and improved global accessibility, strengthening the fight against respiratory diseases.

What Market Trends Are Driving the Expansion of Respiratory Disease Vaccines?

The increasing adoption of combination vaccines, which protect against multiple respiratory infections in a single dose, has gained popularity due to convenience and improved immunization coverage. Additionally, the expansion of universal immunization programs and government-funded vaccine distribution initiatives has contributed to market growth. The rise of travel-related vaccinations and employer-sponsored immunization programs has further expanded vaccine accessibility. Additionally, the growing focus on needle-free vaccine delivery, including intranasal and microneedle patch vaccines, is enhancing patient compliance, particularly among pediatric and geriatric populations. As vaccine technology continues to evolve, new formulations targeting emerging respiratory pathogens are being developed, ensuring long-term market sustainability.

What Are the Key Growth Drivers of the Respiratory Disease Vaccine Market?

The growth in the global respiratory disease vaccine market is driven by rising global disease burdens, advancements in vaccine technology, and increased government and private sector investments in immunization programs. The rapid development and deployment of COVID-19 vaccines have demonstrated the potential for accelerated vaccine innovation, paving the way for more efficient vaccine production pipelines. Additionally, the expansion of pediatric and adult vaccination programs, coupled with initiatives promoting vaccine equity in low-income regions, is fueling market growth. The integration of AI and big data analytics in vaccine research is also enhancing strain monitoring and outbreak prediction, supporting proactive vaccine development. As global healthcare systems prioritize respiratory disease prevention, the respiratory vaccine market is expected to witness continuous growth, shaping the future of infectious disease management.

SCOPE OF STUDY:

The report analyzes the Respiratory Disease Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine); Age Group (Pediatric, Adult); Infection (COVID-19, Influenza, Respiratory Syncytial Virus, Pneumonia, Others); Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Altimmune, Inc.
• Arcturus Therapeutics
• AstraZeneca plc
• Bavarian Nordic
• Bharat Biotech
• BioNTech SE
• CanSino Biologics Inc.
• Clover Biopharmaceuticals
• CSL Limited
• CureVac AG
• Dynavax Technologies Corporation
• GeoVax Labs, Inc.
• GlaxoSmithKline plc (GSK)
• iBio, Inc.
• ImmunityBio, Inc.
• Inovio Pharmaceuticals
• Johnson & Johnson
• Medicago Inc.
• Meissa Vaccines
• Merck & Co., Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.